{
  "docId": "019de074-5234-763a-a0be-96f5f1aa05d9",
  "docSlug": "9279d19020d2e95032dc34a127aaa2e7",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 40 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 39,
  "pageCount": 40,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a list-based structure to summarize drug development progress across three distinct assets.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-5234-763a-a0be-96f5f1aa05d9/39",
  "deckHref": "/decks/019de074-5234-763a-a0be-96f5f1aa05d9",
  "deckJsonHref": "/decks/019de074-5234-763a-a0be-96f5f1aa05d9.json",
  "deckAnchorHref": "/decks/019de074-5234-763a-a0be-96f5f1aa05d9#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.93,
        "x": 0.035,
        "y": 0.18
      },
      "kind": "list",
      "text": "CTX-009 Novel DLL4 x VEGF-A bispecific antibody with both combination and monotherapy activity. Phase 1: Dose response established. BTC Phase 2 results: 37.5% ORR (2L/3L), 63.6% (2L), median PFS 9.4 months, OS 12.5 months. CRC Phase 1 activity.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a93a4eb-b180-45ca-91c1-474993e46b3d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.93,
        "x": 0.035,
        "y": 0.7
      },
      "kind": "list",
      "text": "CTX-8371 Next generation PD-1 x PD-L1 bispecific antibody. Discovered with our StitchMabs platform. Superior activity to commercial PD-1 and PD-L1 inhibitors in preclinical studies. Unique MOA – enhances T-cell activation.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8f54174-4a26-4dc3-bc6d-94d6cb5c9e9f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.93,
        "x": 0.035,
        "y": 0.45
      },
      "kind": "list",
      "text": "CTX-471 Potential best-in-class CD137 agonist antibody with monotherapy activity. Phase 1 monotherapy study fully enrolled. 4 partial responses (PRs) in post PD-1 population. Combination with KEYTRUDA study initiated in 4Q 2022.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7e4cd97-af5e-4d9d-8bbe-c3bf843646d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.29,
        "x": 0.035,
        "y": 0.08
      },
      "kind": "title",
      "text": "Program Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8634a35-1810-438f-acc6-e3c32212ffce",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 40,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f0a32b3c-a238-480c-9a9d-c05166154467",
      "evidence": "The document implies that the current state of cancer treatment is inadequate and that innovative therapies are needed.",
      "position": 0,
      "objective": "The cost of inaction in cancer treatment",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 40,
      "from": 7,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "6979bcd9-f71b-4757-b297-1c4753563587",
      "evidence": "The document presents data and results for each of these therapies.",
      "position": 1,
      "objective": "The potential benefits of CTX-009, CTX-471, and CTX-8371",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.6,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}